Caris Life Sciences secured $310 million in growth capital that will be used to expand the molecular science company’s presence in precision medicine in oncology.
Fujifilm Holdings Corp. said a late-stage study of Avigan showed the antiviral drug reduced recovery times for Covid-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.
Silicon Valley medical equipment startup Visby Medical received Emergency Use Authorization by the U.S. Food and Drug Administration for a portable PCR Covid-19 test kit, the first company to do so, according to the FDA.
Researchers are developing simpler Covid-19 diagnostic tests for use outside of labs in an effort to make mass testing available, fast and inexpensive.
Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.
Locanabio combines gene therapy with RNA modification for a novel, highly flexible platform that can modify, replace or eliminate dysfunctional RNA.
Tesla, the electric car company founded and run by Elon Musk, is building mobile molecular printers to assist Germany’s CureVac in manufacturing an experimental COVID-19 vaccine.
Cambridge, Massachusetts-based Carmine Therapeutics inked a research collaboration deal with Japan’s Takeda Pharmaceutical to develop and commercialize non-viral gene therapies for two rare diseases.
Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.
Cambridge, Massachusetts-based Alnylam Pharmaceuticals released positive Phase III data from the ILLUMINATE-A clinical trial of lumasiran in the treatment of primary hyperoxaluria type 1 (PH1).